whatshot

STOK   $11.43  1.42% Market Closed After Close 11.43 0.0

Stoke Therapeutics Inc
show_chart Advanced Chart of STOK
Last Events:

2023-08-09 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-06 Trend pattern changed from расширяющаяся формация to расходящийся клин с наклоном вниз.

2023-08-06 Signal in RSI changed from bearish recovery to bullish reversal. RSI indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the overbought zone.

2023-08-05 Trend pattern changed from расходящийся треугольник to расширяющаяся формация.

2023-08-05 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-04 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-04 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-03 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 7
Target Price Mean 22.29
Mean unverified/preliminary 22.29 / 22.29
Target Price Low / High 15.00 / 35.00
Median / STD DEV 20.00 / 7.20
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy ActivelyBuy
rsi ActivelyBuy None ActivelyBuy
macd None None None
stoch None None None
ma20 Sell Buy None
ma50 None None None
ma100 None Buy ActivelyBuy
Candlestick PatternNov. 21, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US86150R1077
ceo Dr. Edward M. Kaye M.D., Ph.D.
Website https://www.stoketherapeutics.com
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.